Sector: Health Care
Director information for AZENTA INC (data for year 2025)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Alan J. Malus | Former Corporate Executive Vice President of Thermo Fisher; Director | 66 | ["Bachelor\u2019s Degree, University of Michigan", "MBA, University of Pittsburgh", "Formerly served as Corporate Executive Vice President of Thermo Fisher", "Former President, Laboratory Products and Services at Thermo Fisher", "Over 18 years of executive and operating experience in the life sciences and diagnostics industry", "Global healthcare experience", "Experience in enhancing growth strategies and market expansion"] | ["Human Resources & Compensation", "Nominating & Corporate Governance", "Value Creation"] | 2025 |
| Dipal Doshi | Chief Executive Officer of Entrada Therapeutics, Inc.; CEO | 50 | ["Executive Leadership in Life Sciences/Healthcare", "Public Company Executive Experience", "Growth Strategies and Market Expansion", "Operations Experience"] | ["Audit", "ESG"] | 2025 |
| Dr. Martin D. Madaus | Senior Operating Executive at the Carlyle Group Inc. | 66 | ["Chair"] | ["Audit", "ESG"] | 2025 |
| Dr. Tina S. Nova | Former President of Veracyte’s CLIA U.S. Business | 72 | [] | ["Human Resources & Compensation", "ESG"] | 2025 |
| Erica J. McLaughlin | EVP, CFO and Head of Corporate Strategy at Cabot Corporation; Executive Vice President, CFO and Head of Corporate Strategy | 49 | ["International business experience", "Expertise in financial areas and strategy", "Strong background in accounting and audit", "Experience in mergers, acquisitions and integrations", "Industrial knowledge of life sciences", "Inaugural Chairperson of Cabot\u2019s Diversity and Inclusion Steering Committee", "Co-Chair of the Governance pillar at Cabot\u2019s ESG executive management structure"] | ["Audit", "ESG", "Human Resources & Compensation", "Nominating & Corporate Governance", "Value Creation", "Environmental, Social and Governance (Chair)"] | 2025 |
| Frank E. Casal | Chairperson; Board Chair | 71 | ["Former Vice Chair, Audit, KPMG LLP", "Formerly served as Vice Chair of Audit of KPMG", "Over forty years of experience in audit", "Led the Audit function with approximately 9,000 professionals", "Expertise in financial reporting, accounting and audit", "Experience with large, global Fortune 500 companies", "Expertise in mergers and acquisitions, financing transactions, and strategic priorities"] | ["Audit", "Nominating and Governance"] | 2025 |
| John P. Marotta | President and Chief Executive Officer; Chief Executive Officer of Azenta, Inc. | 46 | ["Executive Leadership in Life Sciences/Healthcare", "Global Business", "Investment Management", "Growth Strategies and Market Expansion", "Operations Experience"] | [] | 2025 |
| Martin Madaus | Director | 66 | ["PhD, Veterinary Medicine, Tieraerztliche Hochschule Hannover", "DVM, Veterinary Medicine, Ludwig-Maximilians Universit\u00e4t M\u00fcnchen", "Senior Operating Executive at the Carlyle Group Inc.", "Experience in strategy, mergers and acquisitions, and commercial transformations", "Former Chairman, President and CEO of Millipore Corporation", "Former Chairman and CEO at Other-Clinical Diagnostics", "Former President and CEO, N.A. of Roche Diagnostics Corp"] | ["Nominating and Governance"] | 2025 |
| Quentin G. Koffey | Director | 48 | ["Founder, Managing Partner and CIO of Politan Capital Management", "Partner at Senator Investment Group LP from 2019 to 2021", "Portfolio Manager for Strategic Investments at The D.E. Shaw Group from 2017 to 2019", "Portfolio Manager at Elliott Management Corporation from 2010 to 2017", "Expertise in risk and investment management, strategy, financial management and governance"] | ["Human Resources and Compensation", "Value Creation"] | 2025 |
| Robyn C. Davis | Managing Director at AngelHealthcare Investors | 64 | ["Managing Director of AngelHealthcare Investors", "Investor-focused perspective", "Strong financial acumen", "Experience supporting life sciences companies", "Executive Leadership in Life Sciences/Healthcare", "Risk and Investment Management", "Operations Experience", "Growth Strategy and Market Expansion", "M&A and Integration Experience", "Talent and Leadership Development", "Public Company Director Experience"] | ["Human Resources & Compensation", "Chair", "Human Resources and Compensation", "Nominating and Governance"] | 2025 |
| Tina S. Nova | Director | 72 | ["Extensive experience in the creation of start-up companies and the commercialization of products with a focus on molecular diagnostics", "Co-founder, President and CEO of Genoptix Medical Laboratories", "Experience in managing, raising capital and co-founding early-stage biotechnology companies", "Industry veteran in life sciences with experience in building and leading businesses from conception through IPO", "Deep insights into commercial operations, sales and marketing efforts", "Significant experience in mergers, acquisitions and integration", "Provided executive leadership experience in life sciences"] | ["Environmental, Social and Governance", "Human Resources and Compensation"] | 2025 |
| William L. Cornog | Former Head of KKR Capstone; Director | 61 | ["Investment Management", "Growth Strategies and Market Expansion", "Public Company Director Experience", "M&A and Integration Experience", "Fundamental Valuation and Corporate Management Analysis", "Information Security Experience"] | ["Chair", "Value Creation"] | 2025 |
